Search the Newsreel

Phillips 66 Stock Rides A 5-Day Winning Streak To A 15% Gain

Phillips 66 (PSX) stock has experienced a significant surge, gaining 15% over five consecutive trading days, adding approximately $12 billion to its market value and reaching a new 52-week high. This strong performance, which outpaces the S&P 500, is supported by 14.4% revenue growth …

Alphageo (India) Ltd. Share Price News and Price Action

Alphabet leads institutional holders in SpaceX post-IPO with $94B stake

[Apple Store at 5th Ave in Manhattan, New York City] ozgurdonmaz Alphabet's (GOOG [https://seekingalpha.com/symbol/GOOG]) (GOOGL [https://seekingalpha.com/symbol/GOOGL]) initial $900M bet on SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) in 2015 has surged over 100-fold, reaching a value of roughly $94B as of late June. [https://seekingalpha.com/filing/309924027] Alphabet has emerged as …

Alphabet stock holds firm as capex and cloud growth widen

Alphabet's stock remains firm despite increased capital expenditure guidance of $205 billion for 2026 and Q2 revenue of $119.8 billion. The company's Google Cloud segment continues to be a strong growth driver, with an 82% year-over-year revenue increase and a growing backlog of $513.9 …

HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

HC Wainwright has lowered its Q3 2026 EPS estimate for Connect Biopharma (NASDAQ: CNTB) to a loss of $0.30 per share from $0.26, despite the company recently beating Q2 expectations. The firm maintains a "Buy" rating and a $7.00 price target, aligning with the …

Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the …

Bliss GVS Pharma Share Price Target 2027 to 2030: Analyst Outlook

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

Traws Pharma GAAP EPS of -$0.16 beats by $0.06

* Traws Pharma press release [https://seekingalpha.com/pr/20620150-traws-pharma-reports-q2-2026-financial-results-and-provides-business-highlights] (TRAW [https://seekingalpha.com/symbol/TRAW]): Q2 GAAP EPS of -$0.16 beats by $0.06. * Cash and cash equivalents: As of June 30, 2026, the Company had cash and cash equivalents of $5.0 million, compared to $3.8 million as of December 31, …

Amphenol’s 27% quarter cools on 0.6x volume as valuation stretch moves into focus

APH remains in an active weekly trend and near the top of its 52-week range, but the latest pullback came with thin participation and a wide premium to Sharemaestro Fair Value.

Cipher Digital (CIFR) Could Be 46% Undervalued After Weak Q2 Earnings

Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap?

BIOMARIN PHARMACEUTICAL INC. : PIPER SANDLER RAISES TARGET PRICE TO $88 FROM $82

Piper Sandler has increased its target price for BioMarin Pharmaceutical Inc. (BMRN.O) from $82 to $88. This adjustment reflects an updated outlook from the analytical firm regarding the biotechnology company's valuation. The news was reported by Reuters.

Radiopharm Theranostics (ASX:RAD) Sets October FDA Meeting as RAD101 Moves Toward Phase 3

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the Phase 3 trial design for its imaging agent, RAD101. This comes after RAD101 achieved 93% concordance between MRI and PET imaging in its Phase 2b …

GOOGL Is Already Borrowing Billions For AI – Now It’s Reportedly Eyeing Australia’s Bond Market

Alphabet (GOOGL) is reportedly planning to issue Australian dollar bonds, its first such offering in the region, as part of a broader trend of tech giants raising significant debt to fund AI investments. The company recently priced $25 billion in U.S. dollar bonds and …

Do USPH’s Softer Earnings and New CFO Appointment Reveal a Turning Point in Its Strategy?

Price to earnings forward of Cumberland Pharmaceuticals Inc. – NASDAQ:CPIX

What's Going On With Medexus Pharmaceuticals Inc Stock Sunday?

Enterprise value to revenue forward of CF PharmTech, Inc. Class H – HKEX:2652

Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

Amazon, Alphabet, and Microsoft Are Dropping Nearly $600 Billion on Capital Expenditures: 1 Clear Winner Emerges

Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Microsoft (NASDAQ: MSFT) are the world's three biggest cloud computing providers. They are spending a ton of money on adding more computing capacity this year, with Amazon leading the way, on track to spend $220 …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of investors. This investigation follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. …

What Is Alphabet (GOOGL) Betting On With Gemini 3.7 Flash?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Alphabet (NasdaqGS:GOOGL) has released its Gemini 3.7 Flash AI model, aimed at speeding up productivity tasks and coding automation. The rollout of Alphabet's higher …

Triumph Financial (TFIN) Beat Revenue Views, Is The Stock Still Below Fair Value?

Google’s (GOOGL) Latest AI Model Arrives Amid A Bigger Balancing Act

On August 13, Alphabet's (NASDAQ:GOOGL) Google unveiled Gemini 3.7 Flash, a new AI model built for coding and automated business tasks. The launch came without word on when the company's flagship Gemini 3.5 Pro model will arrive, a gap investors have watched closely as …

At US$1,056, Is Parker-Hannifin Corporation (NYSE:PH) Worth Looking At Closely?

This article evaluates Parker-Hannifin Corporation's stock at its current price of US$1,056, suggesting it might be undervalued based on discounted cash flow analysis, which estimates a fair value around US$1,223. It highlights the company's strong financial performance, including a high return on equity and …

Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds

(FENC) and the Role of Price-Sensitive Allocations

This article provides an AI-generated analysis of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), indicating strong near and mid-term sentiment that could extend to the long term, with no resistance levels above the current price suggesting upside potential. It outlines specific institutional trading strategies (Long, Breakout, …

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts …

Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?

West Pharmaceutical Services (WST) has seen significant share price appreciation and currently trades at $349.42, with analysts estimating a fair value of around $404, suggesting it is undervalued by approximately 13.5%. The company's growth is driven by GLP-1 exposure and plans for operational efficiencies, …

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements regarding …

Sundar Pichai Raised Alphabet's Capex Guidance to $205 Billion the Same Quarter Google Cloud's Backlog Hit $514 Billion. Here's Which Number Actually Matters More.

Alphabet's (NASDAQ: GOOGL) latest earnings report put two enormous sums front and center: a full-year capital expenditure guidance range that it increased to as much as $205 billion and a Google Cloud backlog that has climbed to $514 billion. The scales of these figures …

Parker-Hannifin-Aktie hält sich nach Zahlen bei 1.055 Dollar

Maxim Group Keeps Their Buy Rating on Nouveau Monde Mining (NOU)